Biogen’s Phase 1b BIIB080 Tau Reduction Spurs Midyear Study, SPINRAZA Approved
Biogen’s Phase 1b trial of BIIB080 reported significant tau reduction, spurring a midyear proof-of-concept study to assess cognitive benefits with varied dosing regimens. The company received high-dose SPINRAZA approvals in the US, Japan and Europe and expects two Phase 3 LITIFILIMAB readouts in SLE this year.
1. BIIB080 Tau Reduction and Midyear Study
Biogen’s BIIB080 antisense oligonucleotide targeting tau achieved significant reduction in its Phase 1b trial, prompting initiation of a midyear proof-of-concept study aimed at determining whether tau reduction translates into cognitive benefits. The team is exploring multiple dosing regimens and treatment frequencies to optimize efficacy.
2. High-Dose SPINRAZA Approval
The high-dose formulation of SPINRAZA has secured approvals in the US, Japan and Europe, with initial patient uptake and clinician feedback indicating robust market acceptance. This expanded label enhances treatment options for spinal muscular atrophy across key regions.
3. LITIFILIMAB Phase 3 SLE Trials
Biogen is conducting two Phase 3 trials of LITIFILIMAB in systemic lupus erythematosus, with readouts anticipated later this year. The company plans to evaluate the totality of data from both trials to guide potential filing strategies, reflecting precedent for approvals based on combined trial outcomes.
4. Biomarker Adoption and Competitive Portfolio
CMS now permits blood-based biomarkers for LEQEMBI confirmation, accelerating adoption in primary care pilot programs and supporting maintenance therapy decisions versus Kisunla. Meanwhile, SYFOVRE’s significant lesion-growth reduction data and targeted ocular delivery position it favorably in the geographic atrophy market despite competitive dynamics.